Glycoprotein (GP) IIb‐IIIa antagonists inhibit the aggregation of activated platelets. Three
agents are approved for clinical use. In this review, the characteristics of each agent, their …

Background—Treatments for non–ST-segment–elevation myocardial infarction (NSTEMI)
reduce ischemic events but increase bleeding. Baseline prediction of bleeding risk can …

The conventional management of thrombotic and cardiovascular disorders is based on the
use of heparin, oral anticoagulants, and aspirin. Despite remarkable progress in life …

SciELO - Brasil - Guideline for Stable Coronary Artery Disease Guideline for Stable Coronary
Artery Disease Acessibilidade / Reportar erro Brasil Lista alfabética de periódicos Lista temática …

Platelets play a central role in the genesis of post-percutaneous coronary intervention (PCI)
ischemic events. High post-procedural platelet reactivity to adenosine diphosphate …

Objectives: This study sought to evaluate the characteristics, therapies, and outcomes of
patients with chronic kidney disease (CKD) presenting with non–ST-segment elevation …

OBJECTIVES: Extracorporeal membrane oxygenation is a potentially life-saving intervention
in refractory cardiopulmonary failure, but it requires anticoagulation to prevent circuit …

Background—Bivalirudin, a direct thrombin inhibitor, is a widely used adjunctive therapy in
patients undergoing percutaneous intervention (PCI). Thrombin is a highly potent agonist of …

Aim: Massive intracoronary thrombus is associated with adverse procedural results
including failed aspiration and unfavourable reperfusion. In this scenario the best treatment …

It has been shown that bleeding complications are associated with higher mortality rates
among patients undergoing coronary angioplasty. Due to its properties, bivalirudin may …